TY - JOUR
T1 - Conventional and Kampo medicine in the treatment of mild to moderate COVID-19
T2 - A multicenter, retrospective observational study protocol by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-Observation)
AU - Takayama, Shin
AU - Kashima, Masayuki
AU - Namiki, Takao
AU - Ito, Takashi
AU - Ono, Rie
AU - Arita, Ryutaro
AU - Saito, Natsumi
AU - Nakae, Hajime
AU - Irie, Yasuhito
AU - Kobayashi, Seiichi
AU - Yoshino, Tetsuhiro
AU - Ishigami, Tomoaki
AU - Tanaka, Koichiro
AU - Nogami, Tatsuya
AU - Minakawa, Satoko
AU - Nagase, Mahiko
AU - Kashio, Akihiko
AU - Ishige, Tatsuya
AU - Maehara, Hirofumi
AU - Saito, Toshiaki
AU - Sempuku, Sadahiro
AU - Yamazaki, Mayuko
AU - Tahara, Eiichi
AU - Suda, Norio
AU - Nakamoto, Kayo
AU - Mitsuma, Tadamichi
AU - Sato, Hiroko
AU - Shimooki, Osamu
AU - Nakada, Yoshinobu
AU - Abe, Shuichi
AU - Masuda, Takuya
AU - Kai, Hiroki
AU - Yokota, Kenichi
AU - Chiba, Shigeki
AU - Saitoh, Fumihiro
AU - Tanaka, Yutaka
AU - Koizumi, Sayaka
AU - Fujii, Susumu
AU - Katori, Rie
AU - Kainuma, Mosaburo
AU - Nochioka, Kotaro
AU - Chiu, Shih Wei
AU - Kikuchi, Akiko
AU - Suzuki, Tomoko
AU - Mimura, Masaru
AU - Yamaguchi, Takuhiro
AU - Ishii, Tadashi
N1 - Publisher Copyright:
© 2020 The Authors. Traditional & Kampo Medicine published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Oriental Medicine and Japan Society of Medical and Pharmaceutical Sciences for Traditional Medicine
PY - 2021/4
Y1 - 2021/4
N2 - Aim: We present the study protocol of a multicenter, retrospective observational study that aims to investigate the efficacy of the actual treatment (the efficacy of conventional and Kampo medicines) of patients with mild to moderate or suspected coronavirus disease (COVID-19). Methods: This study is designed as a multicenter, retrospective observational study. Outpatients and inpatients will be recruited from Japanese hospitals. The inclusion criteria are as follows: having or suspected to have COVID-19, mild to moderate COVID-19, symptomatic, ≥20 years of age, male or female, able to communicate in Japanese, and treated with conventional and Kampo medicine. The exclusion criteria are: unable to provide informed consent due to dementia, psychosis, or psychiatric symptoms, severe COVID-19, or determined unsuitable for this study. The sample size is set at 1000, as this number of people can be treated at the collaborating medical institutions during the study period. Results: The main outcome is the number of days without fever, with a body temperature of less than 37°C. The secondary outcome is set at common cold-like symptoms other than fever (fatigue, cough, shortness of breath, sputum, diarrhea) and severity of illness and hospitalization up to 14 days after the visit. Trial registration: The trial was registered in the University Hospital Medical Information Network (Reservation No. UMIN000041301) on August 4, 2020. Conclusion: Our study will explore the contribution of conventional and Kampo medicine in the treatment of patients with mild and moderate COVID-19.
AB - Aim: We present the study protocol of a multicenter, retrospective observational study that aims to investigate the efficacy of the actual treatment (the efficacy of conventional and Kampo medicines) of patients with mild to moderate or suspected coronavirus disease (COVID-19). Methods: This study is designed as a multicenter, retrospective observational study. Outpatients and inpatients will be recruited from Japanese hospitals. The inclusion criteria are as follows: having or suspected to have COVID-19, mild to moderate COVID-19, symptomatic, ≥20 years of age, male or female, able to communicate in Japanese, and treated with conventional and Kampo medicine. The exclusion criteria are: unable to provide informed consent due to dementia, psychosis, or psychiatric symptoms, severe COVID-19, or determined unsuitable for this study. The sample size is set at 1000, as this number of people can be treated at the collaborating medical institutions during the study period. Results: The main outcome is the number of days without fever, with a body temperature of less than 37°C. The secondary outcome is set at common cold-like symptoms other than fever (fatigue, cough, shortness of breath, sputum, diarrhea) and severity of illness and hospitalization up to 14 days after the visit. Trial registration: The trial was registered in the University Hospital Medical Information Network (Reservation No. UMIN000041301) on August 4, 2020. Conclusion: Our study will explore the contribution of conventional and Kampo medicine in the treatment of patients with mild and moderate COVID-19.
KW - Conventional treatment, COVID-19, Kampo medicine, prevention for severe stage, protocol, retrospective observational study, symptom relief
UR - http://www.scopus.com/inward/record.url?scp=85108665560&partnerID=8YFLogxK
U2 - 10.1002/tkm2.1271
DO - 10.1002/tkm2.1271
M3 - 学術論文
AN - SCOPUS:85108665560
SN - 2053-4515
VL - 8
SP - 106
EP - 110
JO - Traditional & Kampo Medicine
JF - Traditional & Kampo Medicine
IS - 1
ER -
